This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Clinical Trials
SatraGO1
A Phase III, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Participants With Moderate-To-Severe Thyroid Eye Disease (TED).
Overview
SatraGo1 trial is testing a new potential treatment for Thyroid Eye Disease (TED).
Patients with TED can experience symptoms such as redness, irritation and swelling around the eyes.
The drug being investigated in this study is called Satralizumab. It is a recombinant, humanized anti interleukin (IL)-6 receptor (IL-6R) monoclonal antibody.
The main goal of this study is to learn how safe and tolerable Satralizumab is, and also to assess its effectiveness of reducing TED symptoms. It will be administered as a subcutaneous injection monthly for 14 months, followed by a 4 month review period.
As part of the study, suitable participants will be screened to determine their eligibility.
This study would require participants to attend CERA on a monthly basis for the 18 month duration of the trial.
For further information about this study please contact the Cerulea on 03 8638 5300 or email info@ceruleaclinicaltrials.org.au.
- Principal Investigator
Dr Jwu Jin Khong
SatraGo1 trial is testing a new potential treatment for Thyroid Eye Disease (TED).
Patients with TED can experience symptoms such as redness, irritation and swelling around the eyes.
The drug being investigated in this study is called Satralizumab. It is a recombinant, humanized anti interleukin (IL)-6 receptor (IL-6R) monoclonal antibody.
The main goal of this study is to learn how safe and tolerable Satralizumab is, and also to assess its effectiveness of reducing TED symptoms. It will be administered as a subcutaneous injection monthly for 14 months, followed by a 4 month review period.
As part of the study, suitable participants will be screened to determine their eligibility.
This study would require participants to attend CERA on a monthly basis for the 18 month duration of the trial.
For further information about this study please contact the Cerulea on 03 8638 5300 or email info@ceruleaclinicaltrials.org.au.
- Principal Investigator